Navigation Links
Transforming cancer treatment

A Harvard researcher studying the evolution of drug resistance in cancer is predicting that, in a few decades, "many, many cancers could be manageable."

Martin Nowak, a Harvard Professor of Mathematics and of Biology and Director of the Program for Evolutionary Dynamics, is one of several co-authors of a paper, published in Nature, that details how resistance to targeted drug therapy emerges in colorectal cancers, and suggests a new, multi-drug approach to treatment could make many cancers manageable, if not curable, illnesses.

The key, Nowak's research suggests, is to change the way clinicians battle the disease.

Though physicians and researchers in recent years have increasingly turned to "targeted therapies" new drugs which combat cancer by interrupting its ability to grow and spread rather than traditional chemotherapy, the treatment is far from perfect. Most are only effective for a few months before the cancer evolves resistance to the drugs and is able to grow unchecked.

In the particular colon cancer treatment that was the subject of Nowak's research, the culprit is the KRAS gene. Normally responsible for producing a protein to regulate cell division, when activated, the gene helps cancer cells develop resistance to targeted therapy drugs, effectively making the treatment useless.

Based on analysis completed by Benjamin Allen, a Post-Doctoral Fellow in Mathematical Biology, and Ivana Bozic, a Post-Doctoral Fellow in Mathematics, Nowak's research suggests that, of the billions of cancer cells that exist in a patient, only a tiny percentage about one in a million are resistant to drugs used in targeted therapy. When treatment starts, the non-resistant cells are wiped out. The few resistant cells, however, quickly repopulate the cancer, causing the treatment to fail.

The answer, Nowak argued, is simple rather than the one drug used in targeted therapy, treatments must involve at least two drugs.

Nowak isn't new to such suggestions in 1995, he participated in a study, also published in Nature, that focused on the rapid evolution of drug resistance in HIV. The end result of that study, he said, was the development of the drug "cocktail" many HIV-positive patients use to help manage the disease.

Ultimately, Nowak estimated that hundreds of drugs might be needed to address all the possible treatment variations. The challenge in the near term, he said, is to develop those drugs. Once available, though, he believes the multi-drug approach offers a new avenue for cancer treatment, one that may fundamentally alter how the public views the disease.

"This will be the main avenue for research into cancer treatment, I think, for the next decade and beyond," Nowak said. "As more and more drugs are developed for targeted therapy, I think we will see a revolution in the treatment of cancer."


Contact: Peter Reuell
Harvard University

Related biology news :

1. Preclinical studies use specialized ultrasound to detect presence of cancer
2. Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy
3. Researchers discover molecule in immune system that could help treat dangerous skin cancer
4. Stanford scientists find molecule to starve lung cancer and improve ventilator recovery
5. Tumor microenvironment helps skin cancer cells resist drug treatment
6. Cancer scientists link ‘oncometabolite’ to onset of acute myeloid leukemia
7. The genomics symposium to boost the further development of cancer research
8. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
9. Regulation of telomerase in stem cells and cancer cells
10. 5th Latin American Conference on Lung Cancer
11. Husband-wife team set out to improve breast cancer exams
Post Your Comments:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... NEW YORK , Oct. 29, 2015 /PRNewswire/ ... wearable technology, announced a partnership with 2XU, a ... accessories, to deliver a smart hat with advanced ... runners and other athletes to monitor key biometrics ... of the strategic partnership, the two companies will bring ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences ... today that Mr. Pierre Laurin , President and Chief ... at the upcoming Piper Jaffray 27 th Annual Healthcare ... on December 1-2, 2015. st , at ... one-on-one meetings throughout the day. The presentation will be available ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased to announce that ... facility will be strictly dedicated to basic USP 61, USP 62 and USP 51 ... to have complete chemistry and micro testing performed by one supplier. Management ...
(Date:11/23/2015)... ... November 23, 2015 , ... Shimadzu Corporation announces ... Nexera UC Unified Chromatography system. The award from R&D magazine recognizes Shimadzu’s Nexera ... the year in the analytical and testing category. R&D Magazine chose the Nexera ...
Breaking Biology Technology: